AG
LENZ

Artal Group’s LENZ Therapeutics LENZ Stock Holding History

Artal Group’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100,000
Closed -$2.32M – 144
2022
Q4 		$2.32M Hold
100,000
– – 0.13% 84
2022
Q3 		$2.22M Hold
100,000
– – 0.09% 91
2022
Q2 		$1.93M Hold
100,000
– – 0.1% 98
2022
Q1 		$3.57M Hold
100,000
– – 0.15% 94
2021
Q4 		$8.7M Hold
100,000
– – 0.24% 73
2021
Q3 		$11.5M Hold
100,000
– – 0.26% 74
2021
Q2 		$21.5M Buy
+100,000
New +$17.4M 0.44% 52

Other funds holding LENZ

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.58% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Artal Group's LENZ Position: Q1 2023 in Review

Artal Group sold out of LENZ Therapeutics (LENZ) in Q1 2023, closing a stake of 100,000 shares — an estimated $2.32M sold.

Artal Group first reported a position in LENZ in Q2 2021 and held it in 7 quarters. The position peaked at $21.5M in Q2 2021. 62 funds tracked by Wall St. Rank hold LENZ as of Q1 2023.

  • Artal Group reported no remaining LENZ Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Artal Group sold 100,000 LENZ Therapeutics shares in Q1 2023, an estimated $2.32M.
  • Artal Group first reported a position in LENZ Therapeutics in Q2 2021 and held it in 7 quarters.
  • Artal Group's LENZ Therapeutics position peaked at $21.5M in Q2 2021.
  • 62 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2023.

Based on Artal Group's 13F filing for Q1 2023, filed 12 May 2023.